Literature DB >> 2562982

FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens.

J P Klarnet1, D E Kern, K Okuno, C Holt, F Lilly, P D Greenberg.   

Abstract

Immunization of C57BL/6 (B6) mice with FBL, a Friend murine leukemia virus (F-MuLV), induces both tumor-specific cytolytic CD8+ (CTL) and lymphokine-producing CD4+ Th that are effective in adoptive therapy of B6 mice bearing disseminated FBL leukemia. The current study evaluated the F-MuLV antigenic determinants expressed on FBL that are recognized by FBL-reactive CD8+ and CD4+ T cells. To identify the specificity of the FBL-reactive CD8+ CTL, Fisher rat embryo fibroblast (FRE) cells transfected with plasmids encoding F-MuLV gag or envelope (env) gene products plus the class I-restricting element Db were utilized. FBL-reactive CTL recognized FRE target cells transfected with the F-MuLV gag-encoded gene products, but failed to recognize targets expressing F-MuLV env. Attempts to generate env-specific CD8+ CTL by immunization with a recombinant vaccinia virus containing an inserted F-MuLV env gene were unsuccessful, despite the generation of a cytolytic response to vaccinia epitopes, implying that B6 mice fail to generate CD8+ CTL to env determinants. By contrast, CD4+ Th clones recognized FRE target cells transfected with env and not gag genes, and immunization with the recombinant vaccinia virus induced an env-specific CD4+ T cell response. These data show that in a Friend retrovirus-induced tumor model in which tumor rejection can be mediated by either CTL or Th, antigens derived from discrete retroviral proteins are predominantly responsible for activation of each T cell subset.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562982      PMCID: PMC2189204          DOI: 10.1084/jem.169.2.457

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  41 in total

1.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.

Authors:  D E Kern; J P Klarnet; M C Jensen; P D Greenberg
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

Review 2.  Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes.

Authors:  T J Braciale; L A Morrison; M T Sweetser; J Sambrook; M J Gething; V L Braciale
Journal:  Immunol Rev       Date:  1987-08       Impact factor: 12.988

Review 3.  Cytolytic T lymphocytes.

Authors:  M Nabholz; H R MacDonald
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

4.  Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens.

Authors:  B Chesebro; K Wehrly; M Cloyd; W Britt; J Portis; J Collins; J Nishio
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

5.  Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo.

Authors:  F Plata; P Langlade-Demoyen; J P Abastado; T Berbar; P Kourilsky
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

6.  T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes.

Authors:  J C Leclerc; H Cantor
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

7.  Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.

Authors:  J P Klarnet; L A Matis; D E Kern; M T Mizuno; D J Peace; J A Thompson; P D Greenberg; M A Cheever
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

8.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

9.  Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia.

Authors:  P D Greenberg
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

10.  Identification of an FMR cell surface antigen associated with murine leukemia virus-infected cells.

Authors:  R C Nowinski; S Emery; J Ledbetter
Journal:  J Virol       Date:  1978-06       Impact factor: 5.103

View more
  25 in total

1.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

Review 2.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors.

Authors:  W Chen; H Qin; B Chesebro; M A Cheever
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Immunogenic determinants of a neuropathogenic murine leukemia virus.

Authors:  D S Robbins; M P Remington; M Sarzotti; D St Louis; P M Hoffman
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.

Authors:  K J Hasenkrug; D M Brooks; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

6.  Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells.

Authors:  M Iwashiro; T Kondo; T Shimizu; H Yamagishi; K Takahashi; Y Matsubayashi; T Masuda; A Otaka; N Fujii; A Ishimoto
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach.

Authors:  G Milan; A Zambon; M Cavinato; P Zanovello; A Rosato; D Collavo
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire.

Authors:  Jason Rice; Michelle L Dossett; Claes Ohlén; Sarah L Buchan; Timothy J Kendall; Stuart N Dunn; Freda K Stevenson; Philip D Greenberg
Journal:  Eur J Immunol       Date:  2008-08       Impact factor: 5.532

9.  Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.

Authors:  Jodi L Yorty; Satvir S Tevethia; Todd D Schell
Journal:  Cancer Immunol Immunother       Date:  2007-11-15       Impact factor: 6.968

10.  Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene.

Authors:  M Miyazawa; J Nishio; B Chesebro
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.